In the AMD3100 co-treated group, CXCL12 and CXCR4 levels both decreased compared with OPC group (Fig. 4A; CXCL12, p (OPC vs OPC+AMD) = 0.001, p (NS vs OPC) = 0.017). Here, CXCL12 is linked to age-related macular degeneration.